A US- based medical oncologist shares perspectives on HNSCC epidemiology, in-depth insights into the treatment landscape for locally advanced and for recurrent/metastatic disease, patient progression, and the promising emerging bispecific antibodies.

This interview was conducted on September 08, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.